Visitation to Top Cholesterol Drug Sites Influenced $196 Million in New Starts in 2010

In 2010, visitation to top cholesterol drug sites showed a significant positive influence in driving conversions, as $196 million in new patient starts were associated with lifts in brand awareness and favorability brought about by exposure to these branded sites. Media referred visitation to the drug sites, brought about by banner, text, or display ads, accounted for a third of overall conversions associated with site influence – the largest share. Paid search referred visitation, brought about by paid search engine results, had the second largest share.